Lensar (LNSR) Liabilities and Shareholders Equity (2019 - 2026)
Lensar (LNSR) reported Liabilities and Shareholders Equity of $66.2 million for Q1 2026, down 9.23% year-over-year from $73.0 million in Q1 2025, and down 7.29% quarter-over-quarter from $71.4 million in Q4 2025.
Lensar (LNSR) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Lensar (LNSR) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $66.2 million in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $66.2 million, down 9.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $278.3 million (up 5.93% YoY), and the FY2025 annual result was $71.4 million, up 7.74% from the prior year.
- Liabilities and Shareholders Equity retreated to $66.2 million in Q1 2026 per LNSR's latest filing, from $71.4 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $73.0 million in Q1 2025 and troughed at $52.0 million in Q1 2023.
- A 5-year average of $64.7 million and a median of $66.2 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity slipped 19.53% in 2022, then rose 29.29% in 2023.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $55.8 million in 2022, then gained by 24.61% to $69.6 million in 2023, then retreated by 4.73% to $66.3 million in 2024, then advanced by 7.74% to $71.4 million in 2025, then fell by 7.29% to $66.2 million in 2026.
- Business Quant data shows LNSR's Liabilities and Shareholders Equity at $66.2 million in Q1 2026, $71.4 million in Q4 2025, and $70.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 157.80 Bn | 151.14 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 115.54 Bn | 112.66 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 103.44 Bn | 95.27 Bn | 5.76 Bn | 91.49 Bn |
| 4 | Boston Scientific | 72.38 Bn | 71.17 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 49.76 Bn | 46.09 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 29.53 Bn | 28.42 Bn | 750.30 Mn | 6.63 Bn |
| 7 | GE HealthCare Technologies | 29.51 Bn | 27.44 Bn | 1.98 Bn | 37.13 Bn |
| 8 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 31.92 Bn |
| 9 | Steris | 20.69 Bn | 20.27 Bn | 697.10 Mn | 10.74 Bn |
| 10 | Lensar | 68.71 Mn | 69.00 Mn | 6.38 Mn | 66.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.22 Mn |
| Dec 31, 2025 | 71.43 Mn |
| Sep 30, 2025 | 70.20 Mn |
| Jun 30, 2025 | 70.41 Mn |
| Mar 31, 2025 | 72.96 Mn |
| Dec 31, 2024 | 66.30 Mn |
| Sep 30, 2024 | 62.02 Mn |
| Jun 30, 2024 | 61.41 Mn |
| Mar 31, 2024 | 66.13 Mn |
| Dec 31, 2023 | 69.59 Mn |
| Sep 30, 2023 | 70.85 Mn |
| Jun 30, 2023 | 71.20 Mn |
| Mar 31, 2023 | 51.96 Mn |
| Dec 31, 2022 | 55.84 Mn |
| Sep 30, 2022 | 54.80 Mn |
| Jun 30, 2022 | 58.70 Mn |
| Mar 31, 2022 | 60.30 Mn |
| Dec 31, 2021 | 66.47 Mn |
| Sep 30, 2021 | 68.10 Mn |
| Jun 30, 2021 | 72.48 Mn |